Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

PURPOSE: OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmacokinetics, and preliminary antitumor efficacy in patients with advanced solid tumors. MATE...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Do-Youn, Lee, Se-Hoon, Han, Sae-Won, Kim, Mi-Jung, Kim, Tae-Min, Kim, Tae-You, Heo, Dae Seog, Yuasa, Miyuki, Yanagihara, Yasuo, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614199/
https://www.ncbi.nlm.nih.gov/pubmed/25715763
http://dx.doi.org/10.4143/crt.2014.249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614199/
https://www.ncbi.nlm.nih.gov/pubmed/25715763
http://dx.doi.org/10.4143/crt.2014.249

Ejemplares similares